Successful Use of Tralokinumab in a Pediatric Patient With STAT3 Hyper‐ IgE Syndrome Following Dupilumab‐Associated Conjunctivitis

Documenti analoghi

• Rubinstein–Taybi Syndrome With Severe Eczema, Recurrent Infections, and Hyper IgE Profile Responsive to Dupilumab Treatment
  di: Arti Nanda, et al.
  Pubblicazione: (2025)
• Improvement in Atopic Dermatitis and Recurrent Infection With Dupilumab in Children With Distinct Genetic Types of Hyper‐ IgE Syndrome: A Case Series and Literature Review
  di: Jenna K. Dick, et al.
  Pubblicazione: (2024)
• Effectiveness of Dupilumab and Tralokinumab in Treating Nummular Eczema
  di: Francesca Barei, et al.
  Pubblicazione: (2025)
• Dupilumab‐Induced Psoriasis‐Like Eruption With JAK1 ‐ STAT3 Activation Successfully Treated With Upadacitinib
  di: Yoshihiro Goto, et al.
  Pubblicazione: (2025)
• A Case of Unexpected Successful Treatment of Alopecia Areata With Tralokinumab in a Patient With Atopic Dermatitis
  di: Jacqueline Kussini, et al.
  Pubblicazione: (2025)